[1]

[2]

YAN Caiying, QIN Linying, XU Yaoqing, WANG Xinge, CHAI Nannan, CHEN Long. Research Progress in Uric Acid-Lowering Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 592-595.

[3]

[4]

LIAO Mengfan, ZHONG Liling, XU Yan, LIU Ying, ZHANG Yexiang, CHEN Qingsong, LIU Xudong. Adverse Reactions to Antihypertensive and Hypoglycaemic Drugs Based on Spontaneous Presentation Systems [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 286-291.

[5]

LIU Chenpei, DU Yupeng, LIN Yan. One Case of Anemia Caused by Finerenone Tablets [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 334-336.

[6]

LIU Ying, SONG Xuyu, SUN Rong. Research Progress in Mechanisms of Rhubarb Anthraquinone Based on Hepatic Lipid Regulation and Hepatotoxicity [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1432-1440.

[7]

SUN Xuelin, DU Jiao, TAN Qin, ZHANG Yatong, HU Xin. Real-world data on medications with vitamin injections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1125-1129.

[8]

JIANG Hailun, ZHOU Xinbo, XIAO Dian, ZHONG Wu, LI Song. Proteolysis targeting chimeric drugs and their potential risks [J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 730-734.

[9]

DING Xiaoli, HU Xinyue, WANG Xuelei, SUN Yue, LI Jing, ZHANG Hui, Liang Chenggang, WANG Yan. Quality evaluation of insulin glargine injections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 644-650.

[10]

[11]

LI Mingqi, ZHAO Xiaolu, GAO Xiaoyang, MA Yuehong. Research progress in correlations between epithelial-mesenchymal transition and hepatic fibrosis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 464-468.

[12]

FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.

[13]

JIN Shengju, ZHOU Miao, ZHANG Jianing, GE Gonghui, ZHANG Tingjian, MENG Fanhao. Research progress in novel xanthine oxidase inhibitors and treatment of gout [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 223-228.

[14]

YUE Lanxin, SHEN Pan, ZHOU Lei, HUANG Congshu, ZHOU Wei, GAO Yue. The inhibitory effect and mechanism of Celastrol on adipogenic differentiation in 3T3-L1 [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 65-73.

[15]

WEI Anhua, QI Jianjun, WANG Lu, ZENG Lu, GONG Xuepeng, JIANG Ying. Adverse drug reaction/ event caused by oral antidiabetic drugs [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1415-1420.

PDF (PC)

Knowledge